#1 Clinical Trials Search in Europe

Study Comparing Pirtobrutinib with Idelalisib and Rituximab or Bendamustine and Rituximab for Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

3 1 1 1

What is this study about?

This clinical trial is focused on studying a type of blood cancer known as Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL). The study is comparing the effectiveness of a new treatment called pirtobrutinib (also known by its code name LY3527727) against other treatment options chosen by doctors. These options include a combination of idelalisib and rituximab, or bendamustine and rituximab. The purpose of the study is to see how well these treatments work in patients who have already been treated with a type of medication called a BTK inhibitor.

Participants in the study will be randomly assigned to one of two groups. One group will receive pirtobrutinib as a single treatment, while the other group will receive one of the doctor-chosen combinations. The study will monitor the participants over a period to see how long they can live without the disease getting worse, which is known as progression-free survival. The treatments will be given in different forms, such as tablets taken by mouth or solutions given through a vein.

The study aims to provide valuable information about the effectiveness of pirtobrutinib compared to existing treatment options for patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma. This research could help improve future treatment strategies for these conditions. Participants will be closely monitored throughout the study to ensure their safety and to gather important data on the treatments’ effects.

1 enrollment

Upon joining the study, eligibility is confirmed based on specific criteria such as age, kidney function, and previous treatments.

A signed informed consent form is required, indicating understanding and agreement to comply with study requirements.

2 randomization

Participants are randomly assigned to one of two groups: Arm A or Arm B.

Arm A receives pirtobrutinib as a single treatment.

Arm B receives a combination of either idelalisib and rituximab or bendamustine and rituximab.

3 treatment administration

In Arm A, pirtobrutinib is taken orally in tablet form.

In Arm B, idelalisib is taken orally, while rituximab and bendamustine are administered intravenously.

The specific dosage and frequency are determined by the study protocol and the healthcare team.

4 monitoring and assessments

Regular monitoring is conducted to assess health status and response to treatment.

Assessments include blood tests, imaging, and other evaluations as required by the study.

5 follow-up

After completing the treatment phase, follow-up visits are scheduled to monitor long-term effects and overall health.

The duration of follow-up is specified by the study protocol.

Who Can Join the Study?

  • Must be 18 years or older at the time of joining the study.
  • Must have an estimated creatinine clearance of at least 30 mL/min. This is a measure of how well the kidneys are working.
  • Must be willing and able to give signed informed consent, which means agreeing to the study’s rules and requirements.
  • Must have a confirmed diagnosis of Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) that needs treatment, as defined by specific medical guidelines.
  • Must have been previously treated with a type of medication called a covalent BTK inhibitor.
  • Must have an ECOG performance status of 0 to 2. This is a scale that measures how well a person can perform daily activities.
  • Must have an absolute neutrophil count of at least 0.75 x 109/L without support, or at least 0.50 x 109/L if there is bone marrow involvement. Neutrophils are a type of white blood cell important for fighting infections.
  • Must have a hemoglobin level of at least 8 g/dL, or at least 6 g/dL if there is bone marrow involvement. Hemoglobin is a protein in red blood cells that carries oxygen.
  • Must have a platelet count of at least 50 x 109/L, or at least 75 x 109/L if certain treatments are chosen. Platelets help with blood clotting.
  • Must have AST and ALT levels that are no more than 3 times the upper limit of normal. These are liver enzymes that help assess liver function.
  • Must have a total bilirubin level that is no more than 1.5 times the upper limit of normal. Bilirubin is a substance made during the breakdown of red blood cells.

Who Cannot Join the Study?

  • Patients who have a different type of cancer than Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma cannot participate.
  • Patients who are not within the specified age range for the study cannot participate.
  • Patients who are not part of the specified clinical trial group cannot participate.
  • Patients who are not male or female cannot participate.
  • Patients who are considered part of a vulnerable population, which means they might need special protection or care, cannot participate.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

Site Name City Country Status
Azienda Ospedaliero Universitaria Careggi Florence Italy
Fondazione Policlinico Universitario Agostino Gemelli IRCCS Rome Italy
Uniwersytecki Szpital Kliniczny Im Jana Mikulicza Radeckiego We Wroclawiu Wroclaw Poland

Other Sites

Site Name City Country Status
Fakultni Nemocnice Hradec Kralove Novy Hradec Kralove Czechia
Del-Pesti Centrumkorhaz Orszagos Hematologiai Es Infektologiai Intezet Budapest Hungary
Hopital Beaujon Clichy France
Wojewodzki Szpital Specjalistyczny W Legnicy Legnica Poland
Azienda Ospedaliera Papardo Messina Italy
Csqhik Hecvxmesdee Dcmwcbvkcfmzk Vazdxh La Roche sur Yon France
Ultbvjzagv Om Dlpsskxq Debrecen Hungary
Bgddhkqw Hvdssqyb Dublin Ireland
Vzqqsk doq Rbnjr Uzimptfzjf Hiellmiw Sevilla Spain
Asof Gpzlcd Ozfkpojn Mxzyhbsbjaofb Nwqilrgj Milan Italy
Fxsunigbdv Ieiqw Pgpqgrhgiul Sbs Mkihnx Pavia Italy
Uqvxtoxpzgwfvqehc Dtfme Srzlx Db Vhofdd Verona Italy
Covwqz Hrykfqnogao Rhvrgcsk Ufwgmubhszkec Du Tnrce Tours France
Ivjcy Outvlxtp Pfyqeudrxbd Skr Mgbfbvm Genoa Italy
Uknqwoendbxlbtkydoimw Hwgrhtydgo Acy Heidelberg Germany
Vpnhbimfs Frrkpuaa Nwxpcirts V Prgdt Prague Czechia
Oofevwjzzdvulz Lxvp Gqyv Linz Austria
Igfdksbw fiky Knqlyqryl Tnbcsppprtryqxyeagh ucf Istridslqnht Uao gzcpg Ulm Germany
Usbzuwtxlnwiwuzbgvqcs Sujcwahntpbjpydvot Aio Kiel Germany
Cpqmhv Hflvapgvwdv Lpwt Sad Pierre Benite France
Hhgywuix Umkxrywcsqkfe Mrauwur Dv Vljpxcovqs Santander Spain
Umxhnoehqh Dsnri Sdqcj Dx Bpkjoyw Brescia Italy
Aygyhpyl Zousyhwsqw Dkqvy Roeselare Belgium
Iprxvbkm Tlcqof Bbbx Ghhhzese Pzrzl Iu Bari Italy
Ciudfxv Orlhhedic Zakez Lxcoairsfg Ifx Scc Jlka Z Dmiwh Lublin Poland
Wmwmnvmelfq Wyacspvozafpyxstyofb Csvqtcn Oiqsmxtmm I Tlgkephtredsz Ik Myudzgfzerx W Lgwho Lodz Poland
Fiwwrbhwob Ivvld Sia Gxkwxya Dvt Tkftblp Monza Italy
Kik Zdtnnv Zagreb Croatia
Suiwarr Uzcjidefaklbg Ng 2 In De Jvag Bwjmhvc W Bggmymoqrm Bydgoszcz Poland
Cuveza Hsxgy Brjgbuxpi Rouen France
Pmvkqv Hjrhvntdsed Sjj z olse Katowice Poland
Lgqucvvc Ojwcbefvlpks Syltvwbzjuoohqwqm Luebeck Germany
Hhnypniv Ulyyjkbwgkmmc Qwrucgryqtq Mrsjmw Pozuelo De Alarcon Spain
Pqqucj Scdm Skorzewo Poland
Anbztsq Ozwcbfvuznz Nrfwjnmyk Sy Atoupit E Bbtrkp E C Auddka Aufpbxwvfxb Alexandria Italy
Cfcska Haieqmzvbdi Uswgtqxuaecjm Db Phzgjsqg Poitiers France
Aibozjo Oknxiydhlqu S Mlcpi Dd Tsnmi Terni Italy
Honyocop Scosc Mjnrz Ddylz Mhdwkfmbsnlo Perugia Italy
Ivtmozxi Hsezvebguvk I Tabklgybkryvrai Warsaw Poland
Hsmfpdvv Uobfcleqzbwvc Ifesmhr Lrubfq Madrid Spain
Sxsd Ccrmu Govcjtvuve Salzburg Austria
Shtenlh Swrvjizyqabxvlk W Bgwaqwdcq Pjvkebaeyks Odjnyug Omibfsphnogb Icizgntsxenpzntpnig Brzozow Poland

Want to learn more about this study or check if you can participate? Contact us.

Trial status

Country Status Recruitment Start
Austria Austria
Not recruiting
16.06.2021
Belgium Belgium
Not recruiting
16.06.2021
Croatia Croatia
Not recruiting
16.06.2021
Czechia Czechia
Not recruiting
16.06.2021
France France
Not recruiting
16.06.2021
Germany Germany
Not recruiting
16.06.2021
Hungary Hungary
Not recruiting
16.06.2021
Ireland Ireland
Not recruiting
16.06.2021
Italy Italy
Not recruiting
16.06.2021
Poland Poland
Not recruiting
16.06.2021
Spain Spain
Not recruiting
16.06.2021

Trial locations

Investigated Drugs:

LOXO-305: This is a medication being tested in the trial for its effectiveness in treating chronic lymphocytic leukemia or small lymphocytic lymphoma. It is being used as a single treatment to see how well it works in patients who have already been treated with other BTK inhibitors.

Idelalisib: This medication is used in combination with another drug, rituximab, to treat certain types of blood cancers. In this trial, it is one of the options chosen by the investigator to compare its effectiveness against LOXO-305.

Rituximab: This is a medication that targets specific cells in the immune system and is used to treat various types of blood cancers. In this trial, it is combined with either idelalisib or bendamustine to see how well these combinations work compared to LOXO-305.

Bendamustine: This is a chemotherapy drug used to treat certain types of blood cancers. In this trial, it is combined with rituximab to evaluate its effectiveness against LOXO-305 in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.

Investigated Diseases:

Chronic Lymphocytic Leukemia – This is a type of cancer that affects the blood and bone marrow, characterized by the production of too many abnormal white blood cells. These cells accumulate over time, crowding out healthy blood cells and impairing the immune system. The disease often progresses slowly, and many people may not experience symptoms for years. As it advances, it can lead to swollen lymph nodes, fatigue, and an increased risk of infections. The abnormal cells can also spread to other parts of the body, such as the liver and spleen.

Small Lymphocytic Lymphoma – This is a type of non-Hodgkin lymphoma that primarily affects the lymph nodes. It is closely related to chronic lymphocytic leukemia, with the main difference being the location of the cancerous cells. In small lymphocytic lymphoma, the abnormal cells are mainly found in the lymph nodes rather than the blood and bone marrow. The disease typically progresses slowly, and symptoms may include swollen lymph nodes, fatigue, and night sweats. Over time, it can affect other organs and tissues, leading to further complications.

Trial ID:
2023-507697-40-00
Protocol code:
LOXO-BTK-20020
NCT ID:
NCT04666038
Trial Phase:
Therapeutic confirmatory (Phase III)

Other Trials to Consider

  • Evaluating the efficacy of pirtobrutinib and epcoritamab in patients with untreated Richter transformation of chronic lymphocytic leukemia

    Recruiting

    3 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    Austria Denmark Germany Ireland The Netherlands

  • A study of emavusertib and zanubrutinib in patients with chronic lymphocytic leukemia and other B-cell cancers.

    Recruiting

    2 1 1 1
    Investigated Drugs:
    Italy Spain